Discovering next-generation combination therapies and immunotherapies for lung cancer patients

Description of the granted funding

Lung cancer is the biggest cancer killer in men and the second biggest in women in Finland (Syöpärekisteri, 2018). 10-15% of the adenocarcinomas in non-smoker patients harbor mutations in epidermal growth factor (EGFR) gene. EGFR inhibitors have improved the life expectancy of these patients, but typically drug resistance forms within 9-14 months. Every cell in the tumor is different (=tumor heterogeneity), and only some cells have the capacity to form resistance. Dr. Haikala's research performed in the University of Helsinki is studying how tumor heterogeneity contributes to formation of drug-resistant miroenvironment and therapy resistance. The study aims to find better targeted and immunotherapy combinations for lung cancer patients to achieve long lasting treatment effects. The research utilizes cutting edge research models including microfluidic and organoid 3D cultures from fresh tumor tissue collected from consented patients in collaboration with the University Hospital.
Show more

Starting year

2021

End year

2024

Granted funding

Heidi Haikala Orcid -palvelun logo
297 975 €

Funder

Research Council of Finland

Funding instrument

Postdoctoral Researcher

Other information

Funding decision number

339167

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer